Drug intelligence / Profile preview

pusintin

Development stage
Phase 3
Lead developer
TOT Biopharm
Modality
Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Pusintin is a biosimilar of bevacizumab, developed by TOT Biopharm. It is a humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis—the formation of new blood vessels—which tumors need for growth and metastasis. Pusintin has been approved in China for the treatment of advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), glioblastoma multiforme, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma. The drug was developed using proprietary Perfusion-batch mixed culture technology to optimize production efficiency and cost[1][2][3][5][8].

Brand names
Pusintin
Other names
bevacizumab biosimilarTAB008TAB-008TAB 008
02

Targets

Beyond the preview

Go deeper on pusintin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pusintin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call